Antihyperglycemic and Blood Pressure Effects of Empagliflozin in Black Patients With Type 2 Diabetes Mellitus and Hypertension

Circulation
Keith C FerdinandLeo Seman

Abstract

Empagliflozin, a sodium-glucose cotransporter 2 inhibitor indicated for type 2 diabetes mellitus (T2DM), can lower blood pressure (BP) and reduce cardiovascular mortality in patients with T2DM and preexisting cardiovascular disease. Its effects in blacks have been understudied. In this 24-week study, 150 blacks with T2DM and hypertension had glycohemoglobin (primary end point), office and 24-hour ambulatory BP, body weight, and safety assessments. After a 2-week, open-label, placebo run-in, patients were randomly assigned to once daily empagliflozin (10 mg for the first 4 weeks, then force-titrated to 25 mg until week 24) or placebo. A mixed-effects model for repeated measures was performed on the primary and 2 key secondary end points, and an analysis of covariance for nonrepeated measures with last observation carried forward was performed for 2 other key secondary end points. Hierarchical testing was applied for these end points. Overall, 52.7% of participants were men, mean (SD) age, 56.8 (9.3) years; mean duration of T2DM, 9.3 (7.1) years. The baseline values of key parameters (mean [SD]) were as follows: glycohemoglobin, 8.59 (1.02)%; ambulatory systolic BP, 146.3 (11.0) mm Hg; and ambulatory diastolic BP, 89.4 (8.1) mm H...Continue Reading

References

Jan 1, 1994·American Journal of Hypertension·D D GretlerM B Murphy
Nov 9, 2011·Clinical Trials : Journal of the Society for Clinical Trials·David L MountUNKNOWN Look AHEAD Research Group
Oct 2, 2014·Diabetes Care·Ilkka TikkanenUNKNOWN EMPA-REG BP Investigators
Feb 12, 2015·Clinical Pharmacology and Therapeutics·A RamamoorthyL Zhang
Mar 11, 2015·Journal of Transcultural Nursing : Official Journal of the Transcultural Nursing Society·Rebecca Luebbert, Amelia Perez
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
May 22, 2016·Diabetes Care·Muhammad Abdul-GhaniRalph A DeFronzo
Jul 14, 2016·American Journal of Hypertension·Benjamin Gavish, Joseph L Izzo
Nov 12, 2016·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·John E AndersonCharles F Shaefer
Dec 25, 2016·The Lancet. Diabetes & Endocrinology·Charis Hoppe, David Kerr
Oct 25, 2017·Circulation·Mercedes R CarnethonUNKNOWN American Heart Association Council on Epidemiology and Prevention; Council on Cardiovascular Disease in the Young; Council o
Feb 2, 2018·Circulation·Emelia J BenjaminUNKNOWN American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee
Jul 4, 2018·Circulation·Naveed Sattar, Darren K McGuire

❮ Previous
Next ❯

Citations

Apr 18, 2020·Expert Opinion on Pharmacotherapy·Lakshini Y HeratMarkus P Schlaich
Jun 23, 2019·Current Cardiology Reports·André J Scheen
Sep 26, 2020·American Journal of Hypertension·Karen C Tran, Swapnil Hiremath
May 14, 2020·Current Opinion in Cardiology·Bradley P Deere, Keith C Ferdinand
Feb 20, 2021·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Beichen TianGang Xu
May 4, 2021·Circulation·Kazuomi KarioWanpen Vongpatanasin
Mar 13, 2021·Current Opinion in Cardiology·Peder L MyhreScott D Solomon
Jun 2, 2021·Current Opinion in Cardiology·Muhannad AlqudsiJose Navarrete
Jul 14, 2021·Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association·Adel T OsmanRamadan A M Hemeida
Jul 7, 2021·Hypertension·Kazuomi Kario, Bryan Williams
Aug 18, 2021·Endocrinology and Metabolism Clinics of North America·Nasser MikhailArleen F Brown
Nov 18, 2021·Critical Reviews in Clinical Laboratory Sciences·Reza Mohebi, James L Januzzi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Cardiology Journals

Discover the latest cardiology research in this collection of the top cardiology journals.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.